Recce Pharmaceuticals reaches midpoint in Phase II Trial for Topical Gel R327G

Proactive - Interviews for investors

Recce Pharmaceuticals Ltd (ASX:RCE, FSE:R9Q) CEO James Graham joins Proactive’s Tylah Tully to discuss progress in a Phase II clinical trial for the topical gel RECCE® 327 (R327G). Recce has formally reached the halfway point, with 15 patients successfully dosed. The trial is assessing the efficacy of R327G against Acute Bacterial Skin and Skin Structure Infections (ABSSSI), including diabetic foot infections and other wound infections, which are areas of significant unmet medical need. Early data shows that R327G is well tolerated, with promising antibacterial effects observed across a range of infections. The trial aims to enrol 30 participants by the end of 2024. The clinical study locations have expanded, now including Barwon Health, Australian Clinical Research Network NSW and ACRN Melbourne, increasing access to this novel treatment. The global ABSSSI market was valued at US$1.34 billion in 2023 and is projected to grow to US$2.31 billion over the next decade. An interim clinical review is scheduled for mid-October 2024 with further results expected shortly thereafter. Graham expressed optimism about the trial’s progress and the potential impact of R327G on the growing global healthcare need for effective treatments against drug-resistant bacterial infections. #ProactiveInvestors #ReccePharmaceuticals #ASX #R327G #Phase2Trial #ABSSSI #WoundInfections #DiabeticFootInfections #ClinicalTrial #AntibacterialGel #BroadSpectrumAntimicrobial #SkinInfections #DrugResistantBacteria #HealthcareInnovation #BarwonHealth #ClinicalResearch #Australia #InfectiousDiseases #BacterialInfections #MedicalResearch #Biotechnology #TGA #invest #investing #investment #investor #stockmarket #stocks #stock #stockmarketnews